Compile Data Set for Download or QSAR
Report error Found 217 Enz. Inhib. hit(s) with all data for entry = 11919
TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477669(US10889571, Example 11 | N-(4-(chlorodifluorometho...)
Affinity DataIC50: 0.160nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477770(US10889571, Example 114 | US20240101536, Example 1...)
Affinity DataIC50: 0.25nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477781(US10889571, Example 126 | US20240101536, Example 1...)
Affinity DataIC50: 0.25nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477710(US10889571, Example 51 | US20240101536, Example 51...)
Affinity DataIC50: 0.260nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477875(US10889571, Example 223 | US20240101536, Example 2...)
Affinity DataIC50: 0.260nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477663(US10889571, Example 4 | N-(4-(chlorodifluoromethox...)
Affinity DataIC50: 0.270nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477709(US10889571, Example 50 | US20240101536, Example 50...)
Affinity DataIC50: 0.270nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477807(US10889571, Example 153 | US20240101536, Example 1...)
Affinity DataIC50: 0.280nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477813(US10889571, Example 159 | US20240101536, Example 1...)
Affinity DataIC50: 0.280nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477873(US10889571, Example 221 | US20240101536, Example 2...)
Affinity DataIC50: 0.280nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477762(US10889571, Example 106 | US20240101536, Example 1...)
Affinity DataIC50: 0.290nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477768(US10889571, Example 112 | US20240101536, Example 1...)
Affinity DataIC50: 0.300nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477796(US10889571, Example 142 | US20240101536, Example 1...)
Affinity DataIC50: 0.300nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477681(US10889571, Example 22 | US20240101536, Example 22)
Affinity DataIC50: 0.310nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477736(US10889571, Example 80 | US20240101536, Example 80...)
Affinity DataIC50: 0.310nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477788(US10889571, Example 133 | US20240101536, Example 1...)
Affinity DataIC50: 0.310nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477837(US10889571, Example 185 | US20240101536, Example 1...)
Affinity DataIC50: 0.310nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477694(US10889571, Example 35 | (S)—N-(4-(chlorodifl...)
Affinity DataIC50: 0.320nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477730(US10889571, Example 74 | US20240101536, Example 74...)
Affinity DataIC50: 0.320nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477746(US10889571, Example 90 | US20240101536, Example 90...)
Affinity DataIC50: 0.320nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477666(US10889571, Example 7 | US20240101536, Example 7)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477667(US10889571, Example 9 | US20240101536, Example 9)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477751(US10889571, Example 95 | US20240101536, Example 95...)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477800(US10889571, Example 146 | US20240101536, Example 1...)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477822(US10889571, Example 168 | US20240101536, Example 1...)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477839(US10889571, Example 187 | US20240101536, Example 1...)
Affinity DataIC50: 0.330nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477676(US10889571, Example 17 | N-(4-(chlorodifluorometho...)
Affinity DataIC50: 0.340nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477774(US10889571, Example 118 | US20240101536, Example 1...)
Affinity DataIC50: 0.340nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477795(US10889571, Example 141 | US20240101536, Example 1...)
Affinity DataIC50: 0.340nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477812(US10889571, Example 158 | US20240101536, Example 1...)
Affinity DataIC50: 0.340nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477870(US10889571, Example 218 | US20240101536, Example 2...)
Affinity DataIC50: 0.340nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477798(US10889571, Example 144 | US20240101536, Example 1...)
Affinity DataIC50: 0.350nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477810(US10889571, Example 156 | US20240101536, Example 1...)
Affinity DataIC50: 0.350nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477811(US10889571, Example 157 | US20240101536, Example 1...)
Affinity DataIC50: 0.350nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477716(US10889571, Example 60 | US20240101536, Example 60...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477782(US10889571, Example 127 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477786(US10889571, Example 131 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477790(US10889571, Example 135 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477797(US10889571, Example 143 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477803(US10889571, Example 149 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477804(US10889571, Example 150 | US20240101536, Example 1...)
Affinity DataIC50: 0.360nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM661042(US20240101536, Example 2)
Affinity DataIC50: 0.370nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477691(US10889571, Example 32 | (R)—N8-(4-(chlorodif...)
Affinity DataIC50: 0.370nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477711(US10889571, Example 52 | US20240101536, Example 52...)
Affinity DataIC50: 0.370nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477860(US10889571, Example 208 | US20240101536, Example 2...)
Affinity DataIC50: 0.370nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477664(US10889571, Example 5 | US20240101536, Example 5)
Affinity DataIC50: 0.380nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477670(US10889571, Example 12 | N-(4-(chlorodifluorometho...)
Affinity DataIC50: 0.380nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477702(US10889571, Example 43 | US20240101536, Example 43)
Affinity DataIC50: 0.380nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477819(US10889571, Example 165 | US20240101536, Example 1...)
Affinity DataIC50: 0.380nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1 [64-515](Human)
Terns Pharmaceuticals

US Patent
LigandPNGBDBM477835(US10889571, Example 183 | US20240101536, Example 1...)
Affinity DataIC50: 0.380nMAssay Description:The activity of the enzyme and compound inhibition was tested using an EZ reader microfluidic mobility shift assay (PerkinElmer, Waltham, MA). For in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 217 total ) | Next | Last >>
Jump to: